SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is seeing heightened investor attention as market participants weigh the impact of potential data center regulatory hurdles against significant endorsements and capacity demand from hyperscalers. The community is closely monitoring the company's role as a scalable power solution for AI infrastructure, with sentiment split between technical volatility and long-term bullish outlooks.

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending following the announcement of a multi-billion dollar, six-year GPU services contract, fueling intense community discussion about the company's AI-infrastructure thesis and potential short squeeze scenarios. While bulls are excited by the massive revenue potential and the prospect of institutional rerating, investors are actively debating the financing path for the Maysville facility and the implications of the unnamed customer's warrant package.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is generating intense community discussion as it struggles to break the key $80,000 resistance level, with many traders debating whether this is a precursor to a major breakout or a temporary peak. Market participants are closely watching impending treasury news and bond market updates for further catalysts to fuel the next leg of the rally.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh conflicting signals ahead of its upcoming earnings, balancing news of new hardware price hikes and strategic investments in AI startups against broader market uncertainty and bearish skepticism over chip sector fundamentals. Despite some cooling in retail sentiment, community debate remains intense, focusing on whether upcoming results will justify its valuation or if the sector is nearing a correction.

Talon Metals Corp. engages in the exploration and development of mineral properties. It holds interests in the Tamarack nickel-copper-cobalt and Trairão iron projects. The company was founded on April 5, 2005 and is headquartered in Road Town, British Virgin Islands.

Talon Metals Corp

Talon Metals is generating significant buzz following the market announcement that President and CEO Jack Lundin purchased a substantial amount of stock on the open market, signaling strong insider conviction. The community is actively discussing this move as a bullish catalyst that may set the stage for a new era for the stock as it works through recent price resistance.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing heightened uncertainty after the FDA placed a clinical hold on its RGX-121 gene therapy due to asymptomatic spinal MRI findings, causing the company to delay its BLA resubmission. While the stock has faced significant selling pressure, some community members view the selloff as an overreaction, noting that investigators classified the findings as non-serious and that the company's broader pipeline, including Duchenne and retinal disease candidates, remains on track.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors react to the company's new $1.59 billion USD cash pool and its ongoing capital allocation strategy, which the community is actively debating in light of Bitcoin's recent price rally. Discussions are polarized between those who view the firm as a brilliant proxy for Bitcoin exposure and those concerned about the potential for shareholder dilution.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened investor activity as the community focuses on its Bitcoin treasury strategy and potential short squeeze dynamics, with many users highlighting the stock's role as a high-volatility play correlated to Bitcoin's price action. Investors are actively debating the impact of ongoing share dilution versus the long-term potential of the company's asset holdings.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is generating intense community buzz as traders bet on a potential short squeeze, citing a low public float and ongoing share buyback program. Investors are increasingly focused on the company's autonomous driving and robotaxi potential, with many pointing to the stock as an undervalued play on physical AI and long-term automation.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is trending as investors respond to Ethereum's price surge and expectations surrounding the Clarity Act. The community is actively discussing institutional buy-ins and potential stock price catalysts, with many debating the impact of management's capital allocation strategies on shareholder value.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VSTM  
$ERAS $RVMD  
All three VERASTEM  
TARGET-D registration-directed Phase 2 clinical trials  
now enrolling following first-patient dosing  
across pancreatic, colorectal, and lung cancers  
July 28, 2026 at 4:01 PM EDT 
Verastem Oncology Doses First Patient  
in TARGET-D 203 Phase 2 Registration-Directed Trial  
of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor  
for KRAS G12D-Mutated Metastatic Colorectal Cancer 
 
https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-doses-first-patient-target-d-203-phase-2 
 
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy &amp; in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer 
 
A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab &amp; chemotherapy for frontline treatment of metastatic colorectal cancer 
 
KRAS G12D is one of the most common KRAS variants in metastatic colorectal cancer, occurring in approximately 15% of patients

Tony nguyen

Kevin Bui

Vihul

Josh

bmac6687

TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab and chemotherapy for frontline treatment of metastatic

Verastem, Inc.

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer | Verastem, Inc.

StockTwits Web

Verastem Inc

Erasca Inc

Revolution Medicines Inc

  
All three VERASTEM  
TARGET-D registration-directed Phase 2 clinical trials  
now enrolling following first-patient dosing  
across pancreatic, colorectal, and lung cancers  
July 28, 2026 at 4:01 PM EDT 
Verastem Oncology Doses First Patient  
in TARGET-D 203 Phase 2 Registration-Directed Trial  
of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor  
for KRAS G12D-Mutated Metastatic Colorectal Cancer 
 


 
 
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy & in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer 
 
A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab & chemotherapy for frontline treatment of metastatic colorectal cancer 
 
KRAS G12D is one of the most common KRAS variants in metastatic colorectal cancer, occurring in approximately 15% of patients